Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3310 Target Snapshot

Histone deacetylase 11 · SINGLE PROTEIN · Homo sapiens

1,112Compounds
288Assays
8Approved Drugs
1,438.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Histone deacetylase 11 shows clinical signal disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q96DB2. Start with acute myeloid leukemia, then reuse UniProt Q96DB2 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acute myeloid leukemia, then reuse UniProt Q96DB2 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
acute myeloid leukemia

Histone deacetylase 11 shows clinical signal disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with acute myeloid leukemia because it currently carries clinical signal support. Linked drugs include MOCETINOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Histone deacetylase 11 as ChEMBL target CHEMBL3310, mapped to UniProt Q96DB2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Histone deacetylase 11
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3310
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q96DB2
Histone deacetylase 11
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Histone deacetylase 11 is the right protein anchor across sources, using UniProt Q96DB2 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acute myeloid leukemia is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelHistone deacetylase 11
UniProt AccessionQ96DB2
Component TypeProtein
Sequence Length347 aa

Histone deacetylase 11

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Histone deacetylase 11, mapped to UniProt Q96DB2. Sequence length is 347 aa.

Mapped IDQ96DB2
Review nameHistone deacetylase 11
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Histone deacetylase 11 shows clinical signal disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCETINOSTAT
Clinical signal Phase II
chronic lymphocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCETINOSTAT
Clinical signal Phase II
Hodgkins lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCETINOSTAT
Clinical signal Phase II
leiomyosarcoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCETINOSTAT
Clinical signal Phase II
lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCETINOSTAT
Clinical signal Phase II
myelodysplastic syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugMOCETINOSTAT
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with acute myeloid leukemia because it currently carries clinical signal support. Linked drugs include MOCETINOSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacute myeloid leukemia
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

8
Approved
5
Phase III
6
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC501,385.0
KI53.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2105763 10.15 Ki 0.07 Clinical
CHEMBL3329621 10.0 IC50 0.1 Preclinical
CHEMBL3329622 9.7 IC50 0.2 Preclinical
CHEMBL343448 9.52 IC50 0.3 Approved
CHEMBL2105763 9.43 IC50 0.37 Clinical
CHEMBL5618885 9.05 IC50 0.9 Preclinical
CHEMBL3356916 9.0 IC50 1.0 Preclinical
CHEMBL4130288 9.0 IC50 1.0 Preclinical
CHEMBL483254 8.8 IC50 1.6 Approved
CHEMBL4127020 8.7 IC50 2.0 Preclinical
Distribution

pChEMBL Value Distribution

101
5.0
71
5.5
149
6.0
65
6.5
55
7.0
56
7.5
24
8.0
13
8.5
5
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

GIVINOSTAT
CHEMBL1213492
Approved 2024
PANOBINOSTAT
CHEMBL483254
Approved 2015
BELINOSTAT
CHEMBL408513
Approved 2014
ROMIDEPSIN
CHEMBL343448
Approved 2009
VORINOSTAT
CHEMBL98
Approved 2006
Assay Landscape

Assay Landscape

288
Total Assays
502
Tested Compounds
3
Assay Types
Binding — 284 assays, 502 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 196 308 6.3
cell-based format 70 140 6.0
assay format 16 54 6.7
organism-based format 1 0
subcellular format 1 0
ADME — 3 assays, 4 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 3 4 6.3
Toxicity — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 1 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine